EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate

Marek Lapka

Klinická farmakologie a farmacie · 30.10.2025 · 39 (3) · 174-180

DOI: 10.36290/far.2025.062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinická farmakologie a farmacie, erschienen am 30.10.2025. Verfasst von Marek Lapka. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Lapka, M. (2025). Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate. Klinická farmakologie a farmacie, 39(3), 174-180. https://doi.org/10.36290/far.2025.062

Vancouver

Lapka M. Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate. Klinická farmakologie a farmacie. 2025;39(3):174-180. doi:10.36290/far.2025.062

BibTeX
@article{Lapka2025,
  author = {Lapka, Marek},
  title = {Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate},
  journal = {Klinická farmakologie a farmacie},
  year = {2025},
  volume = {39},
  number = {3},
  pages = {174--180},
  doi = {10.36290/far.2025.062}
}
Kostenlos starten →